Company intelligence / Profile preview

Optigenex

Scottsdale, Arizona, United Statesoptigenex.com ↗

Ownership: Private
Development stage: Commercial

Overview

Optigenex markets ac-11, a patented, all-natural extract of Uncaria tomentosa clinically studied for its DNA repair, immune enhancement, anti-inflammatory, and potential telomere-lengthening effects. Numerous peer-reviewed studies support its use in dietary supplements and topical anti-aging skincare. The product is manufactured to GMP, FDA, and USDA standards and sold globally to supplement and skincare companies.[1][3][5]

Therapeutic areas: OtherDermatologyImmunology
Modalities: Botanical extract
Industry: Food & Nutrition

Drug pipeline

1 asset

ac-11

Commercial

Indications: Aging, Skin conditions

Partnerships

RFI, LLCGeneWize (GeneLink, Inc.)Promethean CorporationCeres Living

Beyond the preview

Go deeper on Optigenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optigenex.

Explore the full profile